Research progress of oncogene and tumor suppressor gene in bladder cancer

Panminerva Medica

Volumn 57, Issue 4, 2015, Pages 191-200

  Zhang, X ^a   Han, C ^b   He, J ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Genes, tumor suppressor; Oncogenes; Urinary bladder neoplasms

Indexed keywords

TUMOR MARKER;

BLADDER TUMOR; GENETICS; HUMAN; METABOLISM; ONCOGENE; TUMOR SUPPRESSOR GENE;

BIOMARKERS, TUMOR; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; URINARY BLADDER NEOPLASMS;

EID: 84992554699     PISSN: 00310808     EISSN: 18271898     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Cheng L, Lopez-Beltran A, Bostwick DG. Bladder pathology. Hoboken, NJ: Wiley-Blackwell; 2012
2. Jemal A, Bray f, Center MM, ferlay J, Ward E, forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
3. Palou J, Algaba f, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumors treated with nonmaintenance bacillus Calmette-Guerin. Eur Urol 2009;56:829-36
4. Liu HB, Kong CZ, Zeng Y, Liu XK, Bi JB, Jiang YJ et al. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urol Oncol 2009;27:277-83
5. Jiang LL, Xie MM, Wang XR, Zhao Y, Wang ZJ. [Value of combined detection of urinary Livin and Survivin mRNA expression in the early diagnosis of bladder cancer] [Chinese Medical Journal]. Chung-Hua i Hsueh Tsa Chih 2013;93:3520-2
6. Liu C, Wu X, Luo C, Hu Z, Yin Z, He Y et al. Antisense oligonucleotide targeting livin induces apoptosis of human bladder cancer cell via a mechanism involving 3. J Exp Clin Cancer Res 2010;29:63
7. Yang D, Song X, Zhang J, Ye L, Wang S, Che X et al. Suppression of livin gene expression by siRNA leads to growth inhibition and apoptosis induction in human bladder cancer T24 cells. Biosci Biotechnol Biochem 2010;74:1039-44
8. Weiss C, von Romer f, Capalbo G, Ott OJ, Wittlinger M, Krause Sf et al. Survivin expression as a predictive marker for local control in patients with highrisk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2009;74:1455-60
9. Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol 2010;183:493-8
10. Sharaf S, Ketat A, Diab I, Dwidar f, Sameh W. Evaluation of tissue and urinary survivin expression in non-muscleinvasive bladder cancer. Original Research Article African Journal of Urology 2012;18:143-8
11. Seth S, Matsui Y, fosnaugh K, Liu Y, Vaish N, Adami R et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 2011;19:928-35
12. findeis-Hosey JJ, Xu H. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem 2012;87:24-9
13. Lee DJ, Xylinas E, Rieken M, Khani f, Klatte T, Wood CG et al. Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol 2014;66:379-85
14. Xylinas E, Cha EK, Khani f, Kluth LA, Rieken M, Volkmer BG et al. Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. J Urol 2014;191:830-41
15. Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K et al. IMP3 predicts aggressive supericial urothelial carcinoma of the bladder. Clin Cancer Res 2008;14:1701-6
16. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deiciency, triggers bladder tumorigenesis. J Clin Invest 2007;117:314-25
17. Buyru N, Tigli H, Ozcan f, Dalay N. Ras oncogene mutations in urine sediments of patients with bladder cancer. J Biochem Mol Biol 2003;36:399-402
18. Knowles MA, Williamson M. Mutation of H-ras is infrequent in bladder cancer: Conirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 1993;53:133-9
19. Bittard H, Descotes f, Billerey C, Lamy B, Adessi GR. A genotype study of the c-Ha-ras-1 locus in human bladder tumors. J Urol 1996;155:1083-8
20. Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA. Activation of RAS family Genes in Urothelial Carcinoma. J Urol 2009;181:2312-9
21. Tuna B, Yorukoǧlu K, Tuzel E, Guray M, Mungan U, Kirkali Z. Expression of p53 and mdm2 and their signiicance in recurrence of supericial bladder cancer. Pathol Res Pract 2003;199:323-8
22. Wang M, Zhang Z, Zhu H, fu G, Wang S, Wu D et al. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res 2008;14:3633-40
23. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 1997;90:739-51
24. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell 1997;90:753-62
25. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. fASEB J 2000;14:2532-9
26. Cheng W, fu D, Wei Z, Xu f, Xu Xf, Liu YH et al. NRP-1 expression in bladder cancer and its implications for tumor progression. Tumour Biol 2014;35:6089-94
27. Wu ZX, Song TB, Li DM, Zhang XT, Wu XL. Overexpression of PTEN suppresses growth and induces apoptosis by inhibiting the expression of survivin in bladder cancer cells. Tumour Biol 2007;28:9-15
28. Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y et al. Hyperplasia and carcinomas in Pten-deicient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006;66:8389-6
29. Sfakianos JP, Lin Gellert L, Maschino A, Gotto GT, Kim PH, Al-Ahmadie H et al. The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder. Seminars and Original Investigations 2014;32:657-62
30. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB et al. Expression status and prognostic signiicance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 2010;116:5517-26
31. Lee H, Choi SK, Ro JY. Overexpression of DJ-1 and HSP90α, and asloss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers. Oncol Lett 2012;3:507-12
32. Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso f, Alder H et al. fEZ1/LZTS1 is downregulated in highgrade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 2002;160:1345-52
33. Knowles MA, Aveyard JS, Taylor Cf, Harnden P, Bass S. Mutation analysis of the 8p candidate tumor suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett 2005;225:121-30
34. Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, Petrocca f et al. fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer Cell 2007;11:275-89
35. Vecchione A, Sevignani C, Giarnieri E, Zanesi N, Ishii H, Cesari R et al. Inactivation of the fHIT gene favors bladder cancer development. Clin Cancer Res 2004;10:7607-12
36. Baffa R, Gomella LG, Vecchione A, Bassi P, Mimori K, Sedor J et al. Loss of fHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 2000;156:419-24
37. Zhang CT, Lu R, Lin YL, Liu RL, Zhang ZH, Yang K et al. The signiicance of fragile histidine triad protein as a molecular prognostic marker of bladder urothelial carcinoma. J Int Med Res 2012;40:507-16
38. Salah Z, Aqeilan R, Huebner K. WWOX gene and gene product: Tumor suppression through speciic protein interactions. future Oncol 2010;6:249-59
39. Edwards J, Duncan P, Going JJ, Watters AD, Grigor KM, Bartlett JM. Identiication of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 2002;196:380-5
40. Guo Y, Chekaluk Y, Zhang J, Du J, Gray NS, Wu CL et al. TSC1 involvement in bladder cancer: Diverse effects and therapeutic implications. J Pathol 2013;230:17-27
41. Sjodahl G, Lauss M, Gudjonsson S, Liedberg f, Hallden C, Chebil G et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 2011;6:e18583
42. Pymar LS, Platt fM, Askham JM, Morrison EE, Knowles MA. Bladder tumor-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum Mol Genet 2008;17:2006-17
43. Mhawech-fauceglia P, Alvarez V, fischer G, Beck A, Herrmann fR. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial BC. Am J Clin Pathol 2008;129:918-23
44. Nadal R, Bellmunt J. New treatments for bladder cancer: when will we make progress?. Curr Treat Options Oncol 2014;15:99-114
45. Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, Chang SG et al. frequent alteration of p63 expression in human primary BCs. Cancer Res 2000;60:3370-4
46. Mursi K, Agag A, Hammam O, Riad M, Daw M. The expression of p63 in bladder cancer vs. chronic bilharzial bladder. Arab Journal of Urology 2013;11:106-12
47. Gaya JM, Lopez-Martinez JM, Karni-Schmidt O, Bonal DM, Algaba f, Palou J et al. DeltaNp63 (ΔNp63) expression is a protective factor of progression in clinical High Grade T1 bladder cancer. J Urol 2015;193:1144-50
48. feng Z, Hu W, Rom WN, Beland fA, Tang MS. N-hydroxy-4-aminobiphenyl-DNA binding in human p53 gene: Sequence preference and the effect of C5 cytosine methylation. Biochemistry 2002;41:6414-21
49. Malats N, Bustos A, Nascimento CM, fernandez f, Rivas M, Puente D et al. P53 as a prognostic marker for bladder cancer: A metaanalysis and review. Lancet Oncol 2005;6:678-86
50. Wei M. Carci-nogenicity of dimethylarsinic acid in male f334 ratsand genetic alterations ininduced urinary bladder tumors. Cancino-Genesis 2002;23:1387-97
51. Sanchez-Carbayo M, Socci ND, Lozano J, Saint f, Cordon-Cardo C. Deining molecular proiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89
52. Jankevicius f, Goebell P, Kushima M, Schulz WA, Ackermann R, Schmitz-Drager BJ. p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer. Urol Int 2002;69:174-80
53. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Zf, Sheinfeld J, fair WR et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993;85:53-9
54. Lenz P, Pfeiffer R, Baris D, Schned AR, Takikita M, Poscablo MC et al. Cellcycle control in urothelial carcinoma: Large-scale tissue array analysis of tumor tissue from Maine and Vermont. Cancer Epidemiol Biomarkers Prev 2012;21:1555-64
55. Balbas-Martinez C, Rodriguez-Pinilla M, Casanova A, Dominguez O, Pisano DG, Gomez G et al. ARID1A alterations are associated with fGfR3-wild type, poorprognosis, urothelial bladder tumors. PLoS One 2013;8:e62483
56. Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L. Urothelial dysplasia and other lat lesions of the urinary bladder: Clinicopathologic and molecular features. Hum Pathol 2010;41:155-62
57. Al Hussain TO, Akhtar M. Molecular basis of urinary bladder cancer. Adv Anat Pathol 2013;20:53-60
58. Lu ML, Wikman f, Orntoft Tf, Charytonowicz E, Rabbani f, Zhang Z et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and arraybased methods. Clin Cancer Res 2002;8:171-9
59. Liu ZH, Bao ED. Quantitative assessment of the association between TP53 Arg72Pro polymorphism and bladder cancer risk. Mol Biol Rep 2013;40:2389-95
60. Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M et al. Reactivation of p53 by a speciic MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Therap 2009;7:1533-42
61. Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancerspeciic survival after radical cystectomy. Eur Urol 2013;64:465-71
62. Shariat Sf, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B et al. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int 2014;113:70-6
63. Shariat Sf, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003;61:1140-5
64. Qureshi KN, Grifiths TR, Robinson MC, Marsh C, Roberts JT, Lunec J et al. Combined p21WAf1/CIP1 and p53 overexpression predict improved survival in muscleinvasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1234-40
65. Gakis G, Schwentner C, Todenhofer T, Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer [Review]. BJU Int 2012;110:233-7
66. Jankevicius f, Goebell P, Kushima M, Schulz WA, Ackermann R, Schmitz-Drager BJ. p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer. Urol Int 2002;69:174-80
67. See WA, Zhang G, Chen f, Cao Y. p21 Expression by human urothelial carcinoma cells modulates the phenotypic response to BCG. Urologic Oncology: Seminars and Original Investigations 2010;28:526-33
68. Hosny M, Behnsawy HM, Medhat A. Expression of cell cycle-as sociated proteins in non-muscleinvasive bladder cancer: Correlation with intravesical recurrence following transurethral resection. Urol Oncol 2009;29:495-501
69. Celis JE, Celis P, Palsdottir H, Ostergaard M, Gromov P, Primdahl H et al. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics 2002;1:269-79
70. Lenz P, Pfeiffer R, Baris D, Schned AR, Takikita M, Poscablo MC et al. Cellcycle control in urothelial carcinoma: Large-scale tissue array analysis of tumor tissue from Maine and Vermont. Cancer Epidemiol Biomarkers Prev 2012;21:1555-64
71. Lin HH, Ke HL, Wu WJ, Lee YH, Chang LL. Hypermethylation of E-cadherin, p16, p14, and RASSf1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection. Urol Oncol 2012;30:177-81
72. Bartoletti R, Cai T, Nesi G, Girardi L, Baroni G, Dal Canto M. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by supericial bladder cancer. J Surg Res 2007;143:422-7
73. Nakazawa K, Murata S, Yuminamochi T, Ishii Y, Ohno S, Naka-zawa T et al. p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. Am J Clin Pathol 2009;132:776-84
74. Gakis G, Schwentner C, Todenhofer T, Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer [Review]. BJU Int 2012;110:233-7
75. Jarmalaite S, Andrekute R, Scesnaite A, Suziedelis K, Husgafvel-Pursiainen K, Jankevicius f. Promoter hypermethylation in tumor suppressor genes and response to interleukin-2 treatment in bladder cancer: A pilot study. J Cancer Res Clin Oncol 2010;136:847-54.